Lumen Technologies (LUMN) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Jim Breen - Senior VP - IRKate Johnson - President and CEOChris Stansbury - EVP and CFONick Del Deo - Managing DirectorFrank Louthan - Managing Director Conference Call Participants Michael Rollins - AnalystBatya Levi - Managing Director - Communications, Media & Infrastructure AnalystJim Schneider - Senior Equity AnalystGregory Williams - AnalystJonathan Chaplin - Lead Analyst Operator Greetings, and welcome to th ...

Financial Data and Key Metrics Changes - In the first quarter, the company delivered 1,200,000 total results to patients, with core revenue growing by 11% and non-GAAP operating expenses increasing by only 4%, leading to a more than 60% increase in adjusted EBITDA [6][11][12] - Screening revenue exceeded guidance, increasing by 14% to $540 million, while Precision Oncology revenue grew by 4% to $167 million on a core basis [11][12] - Adjusted EBITDA increased by 61% to $63 million, with adjusted EBITDA margin expanding by 280 basis points [12][18] Business Line Data and Key Metrics Changes - Cologuard growth was driven by rescreens, CareGAP programs, and new ordering providers, with rescreens now accounting for over 25% of total Cologuard orders [11][55] - The CareGAP program grew triple digits last year and is expected to continue strong double-digit growth this year [9][12] - The launch of Cologuard Plus is anticipated to deliver increased value, improved performance, and higher adoption rates [10][19] Market Data and Key Metrics Changes - Customer engagement by the field force increased by over 30% year over year, with more than 190,000 providers ordering during the first quarter, marking a nearly 10% increase year over year [16][32] - The company ended the quarter with cash and securities of $786 million, reflecting a $249 million convertible note paydown [14] Company Strategy and Development Direction - The company is focused on enhancing its commercial execution, with a purpose-built commercial organization and expanded field team engaging providers at record rates [6][8] - The launch of Cologuard Plus is positioned to revolutionize colorectal cancer screening, with a focus on making it the first option in healthcare provider screening toolkits [19][20] - The company is also advancing its precision oncology portfolio with the launch of OncoDetect, aimed at benefiting six million cancer patients [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start in 2025, highlighting the successful launch of two innovative products and the positive impact of commercial improvements [25] - The company expects continued revenue growth, with total revenue guidance increased to between $3.07 billion and $3.12 billion for the year [14][15] - Management noted that they are on track to generate meaningful free cash flow growth through productivity and working capital initiatives [13][14] Other Important Information - The company has taken actions to optimize costs, expecting annual savings of $18 million, with $9 million coming in 2025 [13] - The launch of CancerGuard is planned for the second half of 2025, enabling population-level screening for cancer [24] Q&A Session Summary Question: Focus on commercial execution and changes made - Management highlighted that the volume of calls by sales representatives is up, with a 10% increase in per-rep productivity, indicating an engaged sales force [30][32] Question: Guidance unpacking and revenue outlook - Management indicated that the increased guidance is primarily due to improvements in commercial execution, with expectations of 13% growth in the first half and 15% in the second half of the year [40] Question: Sales and marketing investments - Management acknowledged higher sales and marketing expenses but emphasized that revenue growth significantly outpaced these investments, indicating effective leverage [45] Question: Rescreens contribution to total volume - Management confirmed that rescreens are a significant growth driver and could contribute a couple of points to overall volume this year [56] Question: Blood testing pipeline and timeline - Management expressed confidence in the timeline for blood testing developments, with a readout expected in midsummer [68][79] Question: Cologuard Plus traction and mix - Management reported that Cologuard Plus is currently available for Medicare Part B patients, with expectations for growth as more payers contract for coverage [82][85] Question: Commercial payer discussions and pricing for CancerGuard - Management indicated positive discussions with payers regarding Cologuard Plus and noted that pricing for CancerGuard has not yet been finalized [90]

LendingTree (TREE) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Andrew Wessel - SVP of Investor Relations & Corporate DevelopmentDoug Lebda - Founder, CEORyan Tomasello - Managing DirectorScott Peyree - President & COOJason Bengel - Chief Financial OfficerJohn Campbell - Managing DirectorJed Kelly - Managing Director - Equity ResearchMelissa Wedel - Vice President, U.S. Equities Research Operator Good day and thank you for standing by. Welcome to the LendingTree, Inc. First Quarter tw ...

Rimini Street (RMNI) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Dean Pohl - VP of Investor Relations & TreasurerSeth Ravin - Founder, Chairman, CEO & PresidentMichael Perica - EVP, CFO & Principal Accounting OfficerBrian Kinstlinger - MD, Director of Research & Head of Technology ResearchCole Erskine - Vice President - Equity Research Operator Good afternoon, ladies and gentlemen, and welcome to the Rimini Street Q1 twenty twenty five Earnings Conference Call. At this time, all line ...

Workiva (WK) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Katie White - Senior Director - IRJulie Iskow - President and Chief Executive OfficerJill Klindt - Executive VP & CFOPatrick Schulz - Vice President & Senior Research AssociateRyan Krieger - VP - Software Equity ResearchDominique Manansala - Equity Research AssociateBrett Huff - Managing DirectorJohn Messina - Research Associate Conference Call Participants Steve Enders - AnalystJake Roberge - Equity Research AnalystAdam Hotchk ...

Universal Display (OLED) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Darice Liu - Senior Director of Investor Relations & Corporate CommunicationsSteven Abramson - President, Chief Executive Officer & DirectorBrian Millard - VP, CFO & TreasurerTyler Bisset - Equity Research Associate Conference Call Participants James Ricchiuti - Senior AnalystMehdi Hosseini - Senior Equity Research AnalystScott Searle - Managing Director, Senior Research AnalystNam Hyung Kim - Senior AnalystNone - A ...

Alignment Healthcare (ALHC) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants John Kao - Founder & CEOThomas Freeman - CFORyan Daniels - Group Head–Healthcare Technology and ServicesJohn Ransom - Managing Director, Director of Healthcare ResearchWhit Mayo - Senior Managing DirectorAndrew Mok - Director Conference Call Participants Michael Ha - Senior Research AnalystJessica Tassan - Senior Equity Research AnalystJoanna Gajuk - AnalystMatthew Gillmor - Director & Equity Research AnalystJona ...

Roku (ROKU) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Conrad Grodd - Vice President, Investor RelationsCory Carpenter - Internet Equity ResearchAnthony Wood - Founder, Chairman & CEODan Jedda - Chief Financial OfficerCharlie Collier - President of Roku MediaJustin Patterson - Managing DirectorMustafa Ozgen - President - Devices, Products & TechnologyJames Heaney - SVP - Equity Research Conference Call Participants Brent Navon - AnalystVasily Karasyov - Founder & Senior AnalystLaura ...

Perdoceo Education (PRDO) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Todd Nelson - President & CEOAshish Ghia - Senior VP & CFO Conference Call Participants Nick Nelson - Senior Analyst Operator Hello, and welcome to the Perdocayo Education Corporation First Quarter twenty twenty five Earnings Conference Call. Now I would like to hand the call over to Nick Nelson from Alpha IR. Nick, you may begin. Nick Nelson Thank you, operator. Good afternoon, everyone, and thank you for joining ...

Financial Data and Key Metrics Changes - Total revenue in Q1 was $311 million, up 15% year over year, with international revenue growing 18% year over year [30] - Non-GAAP operating income was $32 million, representing a non-GAAP operating margin of 10% [30] - Current RPO grew 20% year over year, and current deferred revenue grew 15% year over year [31] Business Line Data and Key Metrics Changes - Procore has over 2,400 customers contributing more than $100,000 in ARR, indicating strong customer retention and growth [12] - The company added new customers across various sectors, including a major semiconductor company and a global commercial real estate firm [21][22] Market Data and Key Metrics Changes - International revenue growth was impacted by currency headwinds, with a constant currency growth of 20% year over year [30] - The company noted a steady pipeline and no significant changes in customer plans despite tariff uncertainties [10][36] Company Strategy and Development Direction - Procore is focused on driving digital transformation in the construction industry and enhancing its platform capabilities, including AI integration [11][15] - The company aims to expand its customer base, particularly in underpenetrated segments like owners and specialty contractors, and to increase product cross-sell opportunities [19][20] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about long-term growth despite short-term uncertainties due to tariffs, emphasizing the importance of productivity gains and risk management [10][12] - The company is maintaining its revenue guidance for the full year, expecting revenue between $1.286 billion and $1.290 billion, representing a year-over-year growth of 12% [39] Other Important Information - Procore has initiated a CEO succession plan, with a focus on finding a candidate who shares the company's vision and operational expertise [28][29] - The company returned approximately $100 million to shareholders through share repurchases in Q1 [34] Q&A Session Summary Question: Can you discuss the drivers behind the CRPO acceleration? - Management noted a strong new logo quarter and an increase in contract duration, contributing to the performance [46] Question: What are the early signs of success in international markets? - Management highlighted positive feedback from customers regarding new technical resources and bespoke go-to-market efforts [48][50] Question: How does Procore's value proposition resonate with customers amid uncertainty? - Management emphasized that customers appreciate Procore as a partner, providing more than just software solutions [56] Question: What metrics should be prioritized for measuring progress? - Management indicated that dollar volume is more critical than customer count, focusing on expanding existing customer relationships [78] Question: How is the company managing operational changes during the go-to-market transition? - Management acknowledged some disruption but expressed confidence in the transition's alignment with long-term goals [96]